Benjamin H Laniakea, MD
Family Practice · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Laniakea’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A134882 · Current
Licensed to practise in California · since 2015 · expires 2028-07-31 · State University of New York at Buffalo School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$7,373
Medicare paid this office $7,373 for 72 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 52 | $5,121 | $61 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 19 | $1,261 | $66 |
| Short return visit (20+ min) | 13 | $738 | $53 |
Who their Medicare patients are
72 Original Medicare patients in 2024. Average age 69 · Women 47% · Also on Medicaid 26% · Health risk score 0.91. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 56% · Depression 28% · Diabetes 22% · Cancer 17%.
The office billed $58,517, Medicare allowed $11,223 and paid $7,373; for 127 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 72 | 127 | 69 | 0.91 | $58,517 | $7,373 |
| 2023 | 60 | 109 | 69 | 0.69 | $46,357 | $6,790 |
| 2022 | 61 | 108 | 71 | 0.88 | $53,294 | $6,458 |
| 2021 | 68 | 119 | 71 | 0.84 | $57,814 | $6,864 |
| 2020 | 73 | 153 | 71 | 1.40 | $54,148 | $10,369 |
| 2019 | 61 | 87 | 72 | 0.91 | $17,598 | $6,185 |
| 2018 | 61 | 84 | 73 | 0.98 | $14,732 | $4,889 |
| 2017 | 64 | 119 | 72 | 1.21 | $25,586 | $6,955 |
| 2016 | 35 | 42 | 70 | 1.10 | $7,582 | $2,545 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 47 | $4,725 | $58 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $1,060 | $82 |
2022: 2 services
| Return visit (30+ min) | 45 | $4,557 | $62 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 14 | $790 | $56 |
2021: 2 services
| Return visit (30+ min) | 50 | $5,154 | $61 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 14 | $690 | $49 |
2020: 4 services
| Return visit (30+ min) | 41 | $4,530 | $68 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 15 | $2,148 | $143 |
| Telephone medical discussion with physician, 11-20 minutes | 27 | $1,583 | $44 |
| Short return visit (20+ min) | 19 | $1,099 | $46 |
2019: 3 services
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 13 | $1,835 | $141 |
| Short return visit (20+ min) | 32 | $1,650 | $42 |
| Return visit (30+ min) | 16 | $1,364 | $72 |
2018: 1 service
| Short return visit (20+ min) | 38 | $2,046 | $40 |
2017: 3 services
| Short return visit (20+ min) | 35 | $1,871 | $41 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 11 | $1,524 | $139 |
| Short return visit | 24 | $636 | $19 |
2016: 1 service
| Short return visit (20+ min) | 20 | $957 | $46 |
Drugs they prescribed that Part D paid
$84,488
Pharmacies billed $84,488 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
498 generic and fewer than 11 brand-name prescriptions · $84,488 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Descovy | 11 | $28,079 | $2,553 |
| Emtricitabine-Tenofovir Disop | 23 | $15,786 | $686 |
| Valacyclovir | 15 | $1,454 | $97 |
| Gabapentin | 11 | $1,062 | $97 |
| Testosterone Cypionate | 23 | $853 | $37 |
See all 16 drugs
| Descovy | 11 | $28,079 | $2,553 |
| Emtricitabine-Tenofovir Disop | 23 | $15,786 | $686 |
| Valacyclovir | 15 | $1,454 | $97 |
| Gabapentin | 11 | $1,062 | $97 |
| Testosterone Cypionate | 23 | $853 | $37 |
| Ventolin Hfa | 16 | $816 | $51 |
| Atorvastatin | 46 | $492 | $11 |
| Tamsulosin | 11 | $456 | $41 |
| Lisinopril | 34 | $375 | $11 |
| Rosuvastatin | 29 | $267 | $9 |
| Valsartan | 11 | $251 | $23 |
| Losartan | 14 | $110 | $8 |
| Triamcinolone Acetonide | 13 | $48 | $4 |
| Metoprolol | 12 | $32 | $3 |
| Amlodipine Besylate | 15 | $31 | $2 |
| Hydrochlorothiazide | 11 | $13 | $1 |
Year by year
| 2024 | 569 | 69 | None | None | $84,488 |
| 2023 | 646 | 78 | None | None | $140,786 |
| 2022 | 701 | 116 | None | None | $133,503 |
| 2021 | 738 | 126 | None | 12% | $82,070 |
| 2020 | 687 | 109 | 2% (11) | 13% | $80,273 |
| 2019 | 672 | 77 | 4% (26) | 19% | $90,888 |
| 2018 | 653 | 77 | None | 16% | $54,832 |
| 2017 | 482 | 74 | 4% (19) | None | $33,245 |
| 2016 | 211 | 43 | None | 17% | $24,053 |
| 2015 | 235 | 31 | None | 12% | $6,789 |
| 2014 | 145 | 20 | 0% (0) | 12% | $4,062 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Descovy | 14 | $49,027 | $3,502 |
| Emtricitabine-Tenofovir Disop | 21 | $18,635 | $887 |
| Albuterol Sulfate Hfa | 15 | $1,176 | $78 |
| Gabapentin | 26 | $1,089 | $42 |
| Hydrocortisone | 13 | $661 | $51 |
| Testosterone Cypionate | 12 | $594 | $50 |
| Lisinopril | 51 | $589 | $12 |
| Atorvastatin | 46 | $584 | $13 |
| Carisoprodol | 11 | $451 | $41 |
| Rosuvastatin | 31 | $390 | $13 |
| Promethazine | 14 | $325 | $23 |
| Finasteride | 12 | $275 | $23 |
| Sumatriptan | 12 | $220 | $18 |
| Metoprolol | 16 | $203 | $13 |
| Amlodipine Besylate | 17 | $170 | $10 |
| Losartan | 13 | $146 | $11 |
| Levothyroxine | 13 | $109 | $8 |
| Hydrochlorothiazide | 15 | $40 | $3 |
2022: 13 drugs
| Descovy | 12 | $27,712 | $2,309 |
| Emtricitabine-Tenofovir Disop | 13 | $13,658 | $1,051 |
| Gabapentin | 27 | $1,289 | $48 |
| Atorvastatin | 52 | $539 | $10 |
| Lisinopril | 58 | $498 | $9 |
| Promethazine | 15 | $496 | $33 |
| Levothyroxine | 22 | $411 | $19 |
| Bupropion Hcl Sr | 13 | $381 | $29 |
| Rosuvastatin | 29 | $364 | $13 |
| Tamsulosin | 13 | $307 | $24 |
| Sumatriptan | 13 | $294 | $23 |
| Metoprolol | 20 | $210 | $10 |
| Amlodipine Besylate | 23 | $134 | $6 |
2021: 17 drugs
| Emtricitabine-Tenofovir Disop | 11 | $12,817 | $1,165 |
| Enoxaparin | 14 | $3,143 | $224 |
| Gabapentin | 29 | $1,737 | $60 |
| Atorvastatin | 52 | $600 | $12 |
| Levothyroxine | 25 | $537 | $21 |
| Tamsulosin | 17 | $508 | $30 |
| Rosuvastatin | 21 | $452 | $22 |
| Sumatriptan | 16 | $407 | $25 |
| Promethazine | 21 | $403 | $19 |
| Lisinopril | 53 | $360 | $7 |
| Metoprolol | 17 | $305 | $18 |
| Bupropion Hcl Sr | 12 | $205 | $17 |
| Amlodipine Besylate | 28 | $196 | $7 |
| Omeprazole | 15 | $145 | $10 |
| Triamcinolone Acetonide | 22 | $135 | $6 |
| Metformin Hcl Er | 11 | $113 | $10 |
| Furosemide | 11 | $110 | $10 |
2020: 16 drugs
| Truvada | 12 | $21,495 | $1,791 |
| Enoxaparin | 12 | $3,202 | $267 |
| Gabapentin | 37 | $798 | $22 |
| Metoprolol | 21 | $535 | $25 |
| Atorvastatin | 35 | $512 | $15 |
| Hydroxyzine | 12 | $443 | $37 |
| Rosuvastatin | 18 | $368 | $20 |
| Amlodipine Besylate | 38 | $307 | $8 |
| Lisinopril | 34 | $288 | $8 |
| Levothyroxine | 14 | $274 | $20 |
| Promethazine | 11 | $236 | $21 |
| Losartan | 14 | $231 | $17 |
| Sumatriptan | 12 | $198 | $16 |
| Escitalopram | 15 | $162 | $11 |
| Omeprazole | 17 | $133 | $8 |
| Furosemide | 13 | $94 | $7 |
2019: 19 drugs
| Oxycontin | 13 | $1,236 | $95 |
| Gabapentin | 17 | $1,201 | $71 |
| Metoprolol | 28 | $880 | $31 |
| Rosuvastatin | 13 | $763 | $59 |
| Levothyroxine | 20 | $583 | $29 |
| Loperamide | 12 | $575 | $48 |
| Atorvastatin | 25 | $502 | $20 |
| Amlodipine Besylate | 28 | $264 | $9 |
| Sumatriptan | 21 | $260 | $12 |
| Lisinopril | 31 | $259 | $8 |
| Oxycodone | 12 | $248 | $21 |
| Fluticasone Propionate | 13 | $224 | $17 |
| Carisoprodol | 11 | $159 | $14 |
| Duloxetine | 11 | $145 | $13 |
| Omeprazole | 12 | $116 | $10 |
| Losartan | 13 | $114 | $9 |
| Trazodone | 13 | $96 | $7 |
| Simvastatin | 11 | $48 | $4 |
| Escitalopram | 11 | $41 | $4 |
2018: 16 drugs
| Balsalazide Disodium | 15 | $1,247 | $83 |
| Metoprolol | 23 | $931 | $40 |
| Gabapentin | 23 | $721 | $31 |
| Rosuvastatin | 18 | $630 | $35 |
| Atorvastatin | 37 | $591 | $16 |
| Promethazine | 13 | $468 | $36 |
| Levothyroxine | 16 | $330 | $21 |
| Fluticasone Propionate | 16 | $307 | $19 |
| Lisinopril | 31 | $261 | $8 |
| Omeprazole | 20 | $207 | $10 |
| Amlodipine Besylate | 27 | $196 | $7 |
| Sumatriptan | 17 | $193 | $11 |
| Naproxen | 12 | $129 | $11 |
| Metformin | 12 | $117 | $10 |
| Losartan | 15 | $111 | $7 |
| Hydrochlorothiazide | 13 | $48 | $4 |
2017: 12 drugs
| Atorvastatin | 19 | $346 | $18 |
| Levothyroxine | 11 | $319 | $29 |
| Amlodipine Besylate | 26 | $264 | $10 |
| Oxycodone-Acetaminophen | 13 | $201 | $15 |
| Hydroxyzine | 11 | $132 | $12 |
| Fluticasone Propionate | 12 | $121 | $10 |
| Omeprazole | 20 | $120 | $6 |
| Pramipexole Dihydrochloride | 11 | $96 | $9 |
| Bupropion Hcl Sr | 13 | $79 | $6 |
| Metformin | 12 | $60 | $5 |
| Metoprolol | 17 | $43 | $3 |
| Promethazine | 11 | $26 | $2 |
2016: 3 drugs
| Combivent Respimat | 13 | $4,186 | $322 |
| Ondansetron | 13 | $179 | $14 |
| Bisoprolol | 12 | $163 | $14 |
2015: 3 drugs
| Ondansetron | 24 | $352 | $15 |
| Metoprolol | 19 | $58 | $3 |
| Lisinopril | 17 | $54 | $3 |
2014: 1 drug
| Lisinopril | 21 | $85 | $4 |
Money from drug and device companies
$46 in 2024
| 2024 | 1 | 2 | None | $46 |
| 2019 | 1 | 1 | None | $21 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | None | $46 | 2 payments
|
See all 2 published payments
| Gilead Sciences | Meals · 2024-08-14 | None | $15 |
| Gilead Sciences | Meals · 2024-03-04 | None | $31 |
See earlier years (2019)
2019: $21
| Novo Nordisk | None | $21 | 1 payment
|
Professional record
- NPI
- 1609212042
- Licence
- CA A134882California A134882: Current · expires 2028-07-31
- Trained
- State University of New York at Buffalo School of Medicine, 2013
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-05-13
- NPI last updated
- 2024-04-25
- NPI record certified
- 2024-04-25
This is when the NPI record was last certified, not a medical board exam.